While oral therapy in particular circumstances may be desirable, there is concern that systemic and chronic administration of agents that inhibit VEGF may lead to adverse events including kidney damage and hypertension [145] secondary to VEGF acting as a trophic factor in the retina and kidney. The gene discussed is VEGFA; the disease is hypertensive disorder.